JP Morgan Chase
AMLX icon

JP Morgan Chase’s Amylyx Pharmaceuticals AMLX Stock Holding History

JP Morgan Chase’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,300
Closed -$122K – 7373
2023
Q4 		$122K Buy
+8,300
New +$127K ﹤0.01% 5645

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

JP Morgan Chase's AMLX Position: Q2 2026 in Review

JP Morgan Chase increased its Amylyx Pharmaceuticals (AMLX) stake by 1,067% in Q2 2026, buying an estimated $26.4M and bringing the position to 1,863,650 shares worth $34.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

JP Morgan Chase first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • JP Morgan Chase held 1,863,650 shares of Amylyx Pharmaceuticals worth $34.9M as of Q2 2026.
  • JP Morgan Chase bought 1,703,987 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $26.4M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1753 holding.
  • JP Morgan Chase first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.